Treating Post-Lyme Disease Syndrome With Acetogenins
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04078841|
Recruitment Status : Completed
First Posted : September 6, 2019
Last Update Posted : February 11, 2020
|Condition or disease||Intervention/treatment||Phase|
|Post-Lyme Disease Syndrome (PLDS)||Dietary Supplement: ReaLife+ (RLP) Other: Inert Brown powder||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Using ReaLife+ to Treat Post-Lyme Disease Syndrome|
|Actual Study Start Date :||July 1, 2019|
|Actual Primary Completion Date :||November 14, 2019|
|Actual Study Completion Date :||January 30, 2020|
Active Comparator: ReaLife+ (RLP)
Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
Dietary Supplement: ReaLife+ (RLP)
RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
Placebo Comparator: Inert Brown Powder
Inert brown powder to look similar to RLP
Other: Inert Brown powder
Brown powder Inert brown powder to look similar to RLP
No Intervention: Control
- Blood test [ Time Frame: 3 months ]Western Blot showing "negative"
- PROMIS Fatigue Scale [ Time Frame: 3 months ]Self reported fatigue level changes as measured by the Patient-Reported Outcomes Measurement Information System, Fatigue Scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04078841
|United States, Utah|
|Optimal Health Research|
|Salt Lake City, Utah, United States, 84117|
|Study Chair:||Dr Jeppsen, MD||IRB Chair|